

Original Research Article

Prevalence of Microalbuminuria and Associated Risk Factors in HIV-infected Children seen at a Tertiary Health Centre in the Niger Delta region of Nigeria

Abstract

Aim

This study aimed to assess the prevalence of MA and associated factors in children with HIV attending the paediatric infectious disease clinic (PIDC) at the Federal Medical Centre, Yenagoa (FMCY).

Study Design

Comparative cross-sectional study

Place and duration of study

Paediatric Infectious Disease Clinic (PIDC) and Children Out Patient/Consultant Outpatient Clinic (CHOP) of the FMCY, Bayelsa State between 18th October, 2021 to 10th January, 2022

Methodology

The study involved 150 HIV-infected and 150 uninfected subjects. Subjects with normal urine specific gravity and who tested negative for protein, leukocytes, blood, nitrites, and glucose on urinalysis had their urine assessed for the presence of MA using the Micral Test II. Those who tested positive for MA had their glomerular filtration rate (GFR) estimated, and a renal ultrasound scan was performed. Bivariate and multivariate logistic regression analyses were conducted to identify factors associated with microalbuminuria. The significance level was set at a *P* value less than .05.

Results

The prevalence of MA among HIV-infected subjects (18.7%) was significantly higher than uninfected subjects (2.7%) ($P < 0.001$). The prevalence of microalbuminuria was significantly higher in HIV-infected subjects aged 11-15 years, those who had been living with HIV for over 10 years, those on a regimen containing tenofovir, and those with poor adherence to antiretroviral therapy. Other factors significantly associated with a higher prevalence of MA included clinical stage four HIV disease, advanced immunosuppression, and an unsuppressed viral load. The use of a tenofovir based regimen and having clinical stage four disease were the only predictors of microalbuminuria following multivariate logistic regression (Adjusted OR: 7.87, 95% CI: 1.88 – 70.48, $P = 0.045$, and OR: 14.71, 95% CI: 1.17 – 185.69, $P = 0.038$).

Conclusion

Microalbuminuria was more prevalent in HIV-infected children compared to their uninfected counterparts, with clinical stage four disease being the most significant factor associated with MA.

Keywords: HIV, microalbuminuria, kidney disease, children, antiretroviral therapy.

1. Introduction

Human Immunodeficiency Virus (HIV) infection and Acquired Immune Deficiency Syndrome (AIDS) stand as significant global public health challenges, having claimed over 32 million lives to date[1]. According to the World Health Organization (WHO), there were 38 million people living with HIV/AIDS (PLHIV) in 2019, including 1.4 million children[1]. The first case of AIDS in Nigeria was reported in 1986, initiating a surge in national HIV prevalence from 1.8% in 1991 to a peak of 5.8% in 2001. Subsequently, the prevalence has steadily declined to the

current figure of 1.5% in 2018[2].Nigeria bears the second-highest global HIV burden, with 1.9 million PLHIV as of 2018 [1]. Among Nigerian children aged 0–14 years, the HIV prevalence in 2018 was recorded at 0.2% [1]. Regional disparities are evident, with the South-South zone exhibiting the highest HIV prevalence (3.1%), followed by the North Central zone (2.0%) and the South East zone (1.9%) [2]. Lower prevalence rates are observed in the South West zone (1.1%), the North East zone (1.1%), and the North West zone (0.6%) [2]. Human immunodeficiency virus infection affects various organs within the body, including the kidneys[3].Renal disease in HIV infected children can manifest in different forms, encompassing glomerular conditions like HIV-associated nephropathy (HIVAN), HIV immune complex kidney disease (HIVICK), thrombotic microangiopathy, as well as tubular-interstitial involvement and, less frequently, vasculitis[3].Factors contributing to renal complications in HIV include the direct effect of the virus, opportunistic infections, immune dysregulation, and drug toxicity[3]. Microalbuminuria (MA) represents the earliest indicator of HIV-related kidney disease, denoting abnormal urinary albumin excretion without the presence of proteinuria.[4,5] Several studies on microalbuminuria in HIV infected children have been carried out globally with varying prevalence rates ranging from 0 – 28.8%.[4,6–16]Majority of the studies however, were carried out before tenofovir containing regimen was introduced to the paediatric population and very few regional studies compared the prevalence of microalbuminuria to the individual ART regimens. Also, in spite of these studies, periodic screening for MA has not been incorporated into routine care of HIV-infected children. This study aimed to determine the prevalence of microalbuminuria and associated factors among HIV-infected children attending a paediatric infectious disease unit in a tertiary hospital in the Niger Delta region of Nigeria.

2. Materials and Methods

2.1 Study design and area

It was a comparative cross-sectional, hospital-based study carried out over three months (18thOctober 2021-10th January 2022) in the Paediatric Infectious Disease Clinic (PIDC) and Children Out Patient/Consultant Outpatient Clinic (CHOP/COC) of the Federal Medical Centre, Yenagoa (FMCY), Bayelsa State. The FMCY is presently a 425 bedded Hospital, which provides quality tertiary health care services to meet the needs of the people of Bayelsa State and other neighbouring states [17]. Enrolment into the PIDC commenced in January 2010 and had 232 children living with HIV as at July 2020.

2.2 Study population

The subjects for the study were children aged 18 months – 18 years with HIV infection who attended the PIDC of the FMCY during the study period. The control group were age and sex matched HIV-uninfected children who attended the CHOP/COC of FMCY during the study period. Subjects with the following were excluded: Symptoms suggestive of urinary tract infection (UTI) e.g. dysuria, frequency, urgency, temperature $>38^{\circ}\text{C}$, menstruating females, chronic diseases such as diabetes mellitus, chronic kidney disease, sickle cell anaemia, conventional dipstick urine test positive for protein, blood, glucose, nitrite, leucocyte esterase and alkaline pH (>7.0). Also, those on anti-proteinuric drugs such as steroids, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and those without CD4/viral load results within the past six months.

2.3 Sample size calculation

A sample size of 150 per group was calculated using the Pocock formula for prevalence studies involving two groups [18] with prevalences of microalbuminuria in HIV-infected and uninfected as 11% and 2.5% from previous studies [7,11].

2.4 Sampling technique

A convenience sampling technique was used to recruit subjects. All eligible subjects in the study group who attended the PIDC within the study period and who met the inclusion criteria were consecutively recruited until the sample size was obtained. Consecutive age and gender matched subjects in the control group who attended the CHOP/COC within the study period, who met the inclusion criteria and tested negative to retroviral screening using rapid test kits were also recruited until the sample size was obtained.

2.5 Data collection

After consent and assent were obtained, the biodata was obtained verbally from the caregivers/subjects while the other aspects of the clinical history were extracted from the case notes/care cards. The latest CD4 count/percentage within the past six months was used in classifying the immunological stage. The viral load within the past six months was also noted. Viral suppression was defined as viral load <1000 copies/ml, no suppression ≥ 1000 copies/ml and undetectable levels as viral load <20 copies/ml according to WHO guidelines. Adherence was determined using the self-reporting method [19]. Adolescent patients and their parents/caregivers (for the younger subjects below 10 years of age) were asked to recall how many times they missed taking drugs as prescribed in the preceding two weeks[19]. Patients were classified as having good adherence if they scored $\geq 95\%$ (did not miss more than one dose) and poor adherence if they scored $\leq 95\%$ (missed more than one dose)[19]. For the controls, retroviral screening was done using rapid test kits after pretest counselling at the PIDC after which their biodata was verbally obtained.

Anthropometric measurements including weight and height were taken using standard methods and the values obtained were used to calculate the body mass index (BMI). The weight was

measured to the nearest 0.1kg while height was measured to the nearest 0.1cm. The calculated BMI was interpreted using the WHO BMI charts for age and sex as follows: obese: ≥ 95 th percentile; overweight: 85th to < 95 th percentile; normal: 5th to < 85 th percentile; underweight: < 5 th percentile [20]. Blood pressure (BP) was measured using standard methods with a mercury sphygmomanometer and stethoscope. The BP readings were classified according to the recommendations of the National Blood Pressure Education Program [21].

2.5.1 Urine collection

Each child was given a universal bottle (sample one) labelled with the study number. Those that could not produce urine immediately were encouraged to drink as much water as possible and wait for one hour for urine collection. The parents/subjects were instructed on how to collect about 10 millilitres (ml) of midstream urine. They were advised to clean the tip of the penis or vulva with cotton wool soaked in clean water. About 10ml of urine was then collected after the first part of the urine had been passed with the sample bottle placed about two inches from the genitals avoiding contact with the perineum or adjacent skin. The collected urine was immediately handed over to the researchers/research assistants for testing.

2.5.2 Urine testing

About Five ml of the urine was transferred from sample one to another universal bottle labelled sample two. Then urinalysis was done on sample one using Medi-Test Combi 10R SGL. Those with negative urinalysis findings on sample one, had their sample two tested for microalbuminuria using Micral Test stripR (batch number 47881801)[22]. All children with microalbuminuria between 20 to 200mg/L were considered positive and referred to the paediatric nephrology clinic of the FMCY for appropriate management and follow up. Children with

positive parameters for conventional dipstick were also referred to the paediatric nephrology clinic.

2.5.3 Blood sample collection, testing for serum creatinine and GFR estimation

Venous blood sample (two ml) was collected from subjects with microalbuminuria under standard procedure and sent to the chemical pathology laboratory of FMCY for serum creatinine analysis using standard protocols. The serum creatinine obtained was used to calculate the estimated glomerular filtration rate (eGFR) using the Schwartz formula. The estimated GFR obtained was classified according to the KDIGO clinical practice guideline for the evaluation and management of CKD [23].

2.5.4 Renal ultrasound scan

Renal sonogram was also done for subjects with MA in the Radiology department of FMCY by a consultant radiologist assisted by the researchers. A longitudinal scan of each kidney was done with the patient in prone position and the superior and inferior poles clearly identified and marked. The renal length in centimetres was taken as the longest distance between the poles (bipolar length) and this was compared with the normal renal length expected for the age as either normal, small or enlarged [24]. Renal cortical echogenicity was compared and graded with the echogenicity of the liver and renal medulla. Renal echogenicity was graded according to a standardized score with four categories [24].

2.6 Data analysis

Data was analyzed using the Statistical Package for Social Science (SPSS) software for Windows version 26. Quantitative variables were summarized using mean and standard deviation and compared using Student t test. Qualitative variables were presented using

frequencies and percentages. Chi-square test of proportion was used to assess difference between qualitative variables. Fisher's exact test was applied to correct Chi-squared test values when any cell had a value less than 5. Bivariate and multivariate logistic regression was performed to identify factors associated with microalbuminuria. Level of significance was set at P value less than .05.

2.7 Ethical consideration

Ethical approval for the study was obtained from the Research and Ethics Committee of FMCY (FMCY/REC/ECC/2021/OCTOBER/272). Written informed consent/assent was also obtained from parents/caregivers of the study subjects. All information obtained from the subjects were treated as confidential. Feedback of the outcome of the study was given to caregivers of subjects. Children with microalbuminuria were referred to the paediatric nephrology unit of the FMCY for further evaluation, management and follow up. Children with positive parameters for conventional dipstick (haematuria, proteinuria, pyuria, positive nitrite) were also referred to the paediatric nephrology clinic. The costs of the investigations done during the study were borne by the researchers.

3. Results

3.1 Age and gender distribution of the study participants

A total of 300 children (150 HIV infected and 150 HIV uninfected), were recruited for the study. As shown in Table I, 74 (49.3%) of the HIV infected subjects were males while 76 (50.7%) were females with a male to female ratio of 1:1.02. The HIV uninfected also had similar male to female ratio of 1:1.02. The mean age of the HIV infected and uninfected subjects were 9.73 ± 3.99 and 9.59 ± 3.69 respectively. The age category 11 – 15 years had the highest percentage

frequency in the HIV infected (53.2%) while the age category 6 – 10 years was highest in the HIV uninfected (53.5%).

Table I: Age and gender distribution of the study subjects

Characteristics	HIV infected N (%)	HIV uninfected N (%)	Total N (%)	χ^2	<i>P</i> value
Age					
≤5 years	27 (52.9)	24 (47.1)	51 (100.0)	1.19	0.754
6 -10 years	59 (46.5)	68 (53.5)	127 (100.0)		
11 -15 years	50 (53.2)	44 (46.8)	94 (100.0)		
>15 years	14 (50.0)	14 (50.0)	28 (100.0)		
Gender					
Female	76 (50.0)	76 (50.0)	152 (100.0)	0.00	1.000
Male	74 (50.0)	74 (50.0)	148 (100.0)		

3.2 Prevalence of Microalbuminuria

Thirty-two subjects (10.7%) tested positive for microalbuminuria. The prevalence of microalbuminuria was significantly higher in the HIV infected subjects (18.7%) compared to the HIV uninfected subjects (2.7%) ($P<0.001$) (Table II).

Table II: Prevalence of microalbuminuria in the study subjects

Microalbuminuria	HIV infected	HIV uninfected	Total	Fisher's exact	P value
	N (%)	N (%)	N (%)		
Positive	28 (18.7)	4 (2.7)	32 (10.7)	18.51	<0.001*
Negative	122 (81.3)	146 (97.3)	268 (89.3)		
Total	150 (100.0)	150 (100.0)	300 (100.0)		

3.3 Association between microalbuminuria and age/gender

Those aged 11 – 15 years were eight times more likely to have MA than those aged 6 – 10 years and >15 years. Microalbuminuria was twelve times more likely in those aged 11 – 15 years than those aged ≤5 years (OR:12.24; 95% CI:1.52 – 98.31; $P = 0.018$) [Table III]. The odds of having MA was not statistically significant across gender (OR: 1.58; 95%CI: 0.75 – 3.32; $P = 0.232$) [Table III].

Table III: Association between microalbuminuria and age/gender

Characteristics	Microalbuminuria		Odds Ratio	95% CI	P value
	Yes N (%)	No N (%)			
Age (years)					

≤5	1 (3.7)	26 (96.3)	1		
6 – 10	9 (1.3)	50 (84.7)	4.68	0.56 – 38.98	0.154
11 – 15	16 (32.0)	34 (68.0)	12.24	1.52 – 98.31	0.018*
>15	2 (14.3)	12 (85.7)	4.33	0.36 – 52.58	0.250
Gender					
Female	11 (14.5)	65 (85.5)	1		
Male	17 (23.0)	57 (77.0)	1.58	0.75 – 3.32	0.232

CI is confidence interval, * is statistically significant

3.4 Association between microalbuminuria and age at HIV diagnosis, mode of transmission and duration of infection

There was no significant difference in the odds of having MA based on age at diagnosis and mode of infection. Microalbuminuria was three and five times more likely to be present in those whose duration of infection was >10 years than those with duration between 5 – 10 years and <5 years respectively. (OR: 5.00; 95% CI: 1.06 – 23.62; $P = 0.042$) [Table IV].

Table IV: Association between microalbuminuria and age at HIV diagnosis, mode of transmission and duration of infection

Characteristics	Microalbuminuria		Odds Ratio	95% CI	P value
	Yes N (%)	No N (%)			
Age at diagnosis					

<5years	17 (15.7)	91 (84.3)	0.84	0.17 – 4.24	0.833
5 – 10 years	9 (29.0)	22 (71.0)	1.84	0.33 – 10.25	0.486
>10 years	2 (18.2)	9 (81.8)	1		
Mode of infection					
Vertical	27 (18.7)	117 (81.3)	1.15	0.13 – 10.26	0.898
Horizontal	1 (16.7)	5 (83.3)	1		
Duration of infection					
<5years	2 (7.4)	25 (92.6)	1		
5 – 10 years	10 (14.9)	57 (85.1)	2.19	0.45 – 10.75	0.333
>10 years	16 (28.6)	40 (71.4)	5.00	1.06 – 23.62	0.042*

CI is confidence interval, * is statistically significant

3.5 Association between microalbuminuria and type of treatment regimen, duration on treatment and adherence

As shown in Table V, those on TDF/3TC/DTG were three times more likely to have MA than those on other regimen (OR:2.82; 95% CI: 1.06 – 7.47; $P = 0.037$). Though not statistically significant, MA was twice more likely to be present in those whose duration on HAART was >10 years than those with lesser duration (OR: 2.23; 95% CI: 0.73 – 6.82; $P = 0.159$). Those with poor adherence to HAART were three times more likely to have microalbuminuria than those with good adherence (OR: 3.70; 95% CI:1.33 – 10.00; $P = 0.012$).

Table V: Association between microalbuminuria and type of treatment regimen, duration on treatment and adherence

Characteristics	Microalbuminuria		Odds Ratio	95% CI	P value
	Yes N (%)	No N (%)			
Treatment Regimen					
ABC/3TC/EFV	7 (11.7)	53 (88.3)	1		

TDF/3TC/DTG	16 (27.1)	43 (72.9)	2.82	1.06 – 7.47	0.037*
ABC/3TC/DTG	2 (14.3)	12 (85.7)	1.26	0.23 – 6.85	0.788
ABC/3TC/LPV/r	3 (17.6)	14 (82.4)	1.62	0.37 – 7.09	0.520
Duration on HAART					
<5years	10 (16.4)	51 (83.6)	1		
5 – 10 years	11 (16.7)	55 (83.3)	1.02	0.40 – 2.60	0.367
>10 years	7 (30.4)	16 (69.6)	2.23	0.73 – 6.82	0.159
Adherence to HAART					
Good	20 (15.4)	110 (84.6)	1		
Poor	8 (40.0)	12 (60.0)	3.70	1.33 – 10.00	0.012*

CI is confidence interval, * is statistically significant

3.6 Association between microalbuminuria and clinical, immunologic and virologic disease staging in the HIV infected subjects

Microalbuminuria was seven times more likely to be present in those with stage four disease than those with stage three and one (OR: 7.50; 95% CI:2.28-24.65; $P = 0.001^*$) Those with advanced immunosuppression were two and three times more likely to have MA than those with mild and not significant immunosuppression respectively (OR: 3.77; 95% CI:1.28-11.10; $P= 0.016$) [Table IV]. Those with unsuppressed viral load were four times more likely to have MA than those with suppressed viral load (OR: 4.55; 95% CI:1.89-11.11; $P = 0.001$) [Table VI].

Table VI: Association between microalbuminuria and clinical, immunologic and virologic disease staging in the HIV-infected subjects

Characteristics	Microalbuminuria		Odds Ratio	95% CI	Pvalue
	Yes N (%)	No N (%)			
Clinical Stage					
Stage 1	12 (18.2)	54 (81.8)	1		

Stage 2	0 (0.0)	39 (100.0)	0.00	-	-
Stage 3	6 (20.7)	23 (79.3)	1.17	0.39 – 3.51	0.774
Stage 4	10 (62.5)	6 (37.5)	7.50	2.28-24.65	0.001*
CD4 Count					
Not Significant	15 (13.4)	97 (86.6)	1		
Mild	3 (27.3)	8 (72.7)	2.43	0.58-10.17	0.226
Advanced	7 (36.8)	12 (63.2)	3.77	1.28-11.10	0.016*
Severe	3 (37.5)	5 (62.5)	3.88	0.84-17.94	0.083
Viral load					
Undetected	0 (0.0)	11 (100.0)	0.00	-	-
Suppressed	14 (13.3)	91 (86.7)	1		
Not Suppressed	14 (41.2)	20 (58.8)	4.55	1.89-11.11	0.001*

ABC: Abacavir, 3TC: Lamivudine, DTG: Dolutegravir, LPVr: Lopinavir/ritonavir, TDF: Tenofovir, CI is confidence interval, * is statistically significant

3.7 Multivariate logistic regression analysis of factors with significant association with microalbuminuria in the HIV-infected subjects

Factors that showed significant association with microalbuminuria in the HIVinfected subjects at the bivariate analysis: age group, duration of infection, type of ART regimen, adherence, clinical stage, CD4 count and viral load were used as independent variables in a multivariate binary logistic regression. Tenofovir containing regimen and clinical stage four disease were the only

two factors with significant statistical association with microalbuminuria (adjusted OR: 7.87, 95% CI: 1.88 – 70.48, $P = 0.045$ and OR: 14.71, 95% CI: 1.17 – 185.69, $P = 0.038$) (Table VII).

Table VII: Multivariate logistic regression analysis of factors with significant association with microalbuminuria in the HIV-infected subjects

Factors	β -coefficient	Odds Ratio	95% CI	P value
Gender				
Female		1		
Male	0.71	2.04	0.62 – 6.74	0.242
Age group				
≤ 5 years		1		
6 – 10 years	-2.41	0.09	0.01 – 12.27	0.337
11 – 15 years	-1.74	0.18	0.01 – 42.64	0.534
>15 years		2.32	0.27 – 19.95	0.444

Duration of infection				
<5 years		1		
5 – 10 years	-1.99	0.14	0.01 – 2.69	0.190
>10 years	1.79	5.99	0.05 – 805.61	0.474
Treatment Regimen				
ABC/3TC/EFV		1		
TDF/3TC/DTG	2.06	7.87	1.88 – 70.48	0.045*
ABC/3TC/DTG	0.16	1.18	0.09 – 14.38	0.898
ABC/3TC/LPV/r	1.06	1.21	0.52 – 6.18	0.109
Adherence				
Good		1		
Poor	0.96	2.62	0.27 – 24.84	0.401
Clinical Stage				
Stage 1		1		
Stage 2		0.00	-	-
Stage 3	0.57	0.57	0.08 – 3.80	0.559
Stage 4	2.69	14.71	1.17 – 185.69	0.038*
CD4 Count				
Not significant		1		
Mild	0.54	1.72	0.12 – 25.77	0.694
Advanced	1.03	2.79	0.20 – 39.03	0.446
Severe	0.62	1.85	0.08 – 42.43	0.700
Viral Load				
Undetected		1		
Suppressed		0.00	-	-
Not suppressed	0.21	1.23	0.09 – 16.67	0.876

CI is Confidence Interval, * is statistically significant

3.8 Mean estimated GFR and categories of the subjects with microalbuminuria

The mean GFR for the HIV infected subjects with microalbuminuria ($112.5 \pm 25.1 \text{ ml/min/1.73m}^2$) was significantly lower when compared to the HIV uninfected subjects with microalbuminuria ($153.0 \pm 23.3 \text{ ml/min/1.73m}^2$) ($P = 0.005$). Six (21.4%) of HIV infected subjects who tested positive for microalbuminuria had mildly decreased GFR compared to 0% of their uninfected counterparts who had microalbuminuria. This difference was however not statistically significant ($P = 0.566$).

3.9 Renal length and echogenicity of the subjects with microalbuminuria

Ultrasound scan of the kidneys was done for those with MA but two (HIV uninfected) subjects did not show up for the scan. The mean length of the right kidney for the HIV infected subjects was $8.9 \pm 1.10\text{cm}$ compared to $9.8 \pm 0.42\text{cm}$ for the HIV uninfected subjects. This difference was not statistically significant ($P = 0.282$). The mean length of the left kidney for the HIVinfected subjects was $9.45 \pm 0.98\text{cm}$ compared to $10.2 \pm 0.28\text{cm}$ for the HIV uninfected subjects. This difference was also not statistically significant ($P = 0.300$). All 30 participants scanned had normal (grade 0) renal echogenicity.

4. Discussion

Microalbuminuria was found to be common among HIV infected children in this study with a prevalence of 18.7%. This finding buttresses the need for routine screening for microalbuminuria in HIV-infected children in this setting so as to institute early treatment in order to prevent further progression. Studies with similar prevalence to the index study include that of Ihekaike et al. in Jos (22.2%), Fredrick et al. in Tanzania (20.4%) and Sharma et al. in India (20.5%)[8,13,16]. The reported prevalence in the index study is higher than that by Ezeonwu et al. in Enugu (0%) and Mudi et al. in Kano (6.7%)[6,10]. The index study despite using the same micral test, relatively similar sample size and similar exclusion criteria, reported higher prevalence than the study by Ezeonwuet al. [10]. This difference in prevalence may be attributed to the fact that the subjects in the index study had higher mean duration of HIV infection (6.14 ± 3.31 years) compared to 1.75 ± 1.33 years in the study by Ezeonwuet al. [10]. When compared to the study by Mudi et al. in Kano, the index study used random spot urine sample rather than first morning sample which was used in the study by Mudi et al. [6]. The use of first morning urine sample excludes transient causes of microalbuminuria such as postural changes and vigorous

exercise [5]. The prevalence of microalbuminuria in the index study was lower than that reported by Mosten et al. in Tanzania (28%) [15]. This difference could be attributed to the smaller sample size (150 HIV infected children) used in the index study compared to 330 in the study by Mosten et al. [15]. Also, micral test strip was used in the index study compared to hemocue albumin analyzer used by Mosten et al. [15]. Hemocue albumin analyzer gives exact values of urine microalbumin [15].

The prevalence of microalbuminuria in the HIV uninfected subjects in the index study was 2.7% which is seventimes less than that of the HIV infected subjects. This finding is not surprising as both HIV and its treatment are known to affect the kidneys [9]. Similar prevalence of microalbuminuria in HIV uninfected subjects have been reported by Mistry in South Africa (1%) and Ekulu et al. in Congo (2.5%) [7,14].

In the index study, the prevalence of microalbuminuria was higher in males compared to females, though, statistically not significant. This male predilection has been attributed to hormonal and renal structural differences [11]. Male hormones tend to initiate podocyte apoptosis [11]. This pattern aligns with findings from previous studies [7,9,12–16].

Microalbuminuria was found to be more prevalent in older HIV infected subjects in the present study. The reason for this finding may be because older children may have had HIV infection for a longer duration, with longer exposure to ARVs and thus are more likely to have microalbuminuria [9]. This finding is consistent with studies done by Okechukwu et al. in Abuja, Fredrick et al. in Tanzania and Sharma et al. in India [9,13,16]. However, Iduoriyekemwen et al. in Benin city, found a higher prevalence of microalbuminuria in the younger age group [11]. The reason for this contrasting finding is not obvious. It could be due to the lower mean age of the study subjects in the Benin City study (6.6 ± 3.5 years) compared to 9.73 ± 3.99 years in the

index study[11]. While majority of the study subjects in the index study were six years and above, almost half of the subjects in the Benin City study[11] were less than six years [11].

In this present study, there was a linear relationship between duration of HIV infection and the prevalence of microalbuminuria. It was observed that the prevalence of microalbuminuria was significantly higher in those with duration of HIV infection of more than 10 years. This suggests that there could be progression of renal damage with longer duration of HIV infection. This is similar to previous studies by Eke et al. in Port Harcourt, Ihekaïke et al. in Jos and Fredrick et al. in Tanzania[8,12,13].

In the index study, MA prevalence was significantly higher in subjects with clinical stage 4 disease, advanced immunosuppression and unsuppressed viral load. The association of advanced clinical disease with microalbuminuria can be explained by the fact that as the disease progresses there is profound immune suppression favouring unchecked viral replication and hence kidney involvement. This finding is consistent with those of other studies [9,11,13,15,16]. On the contrary, Mudi et al. found no association between the clinical stage of HIV and microalbuminuria in their study in Kano[6].

The use of tenofovir containing regimen was significantly associated with microalbuminuria in the present study. This finding is significant as tenofovir has been fully introduced to the paediatric population. tenofovir causes renal cell mitochondrial DNA damage leading to oxidative respiratory chain dysfunction [25]. Because of a shortage of adenosine triphosphate (ATP) production, tubular cells cannot properly ensure reabsorption of ions and small molecules, such as microalbumin, potassium, glucose, phosphate, uric acid and amino acids[25]. Therefore, these molecules are secreted in abnormal quantities in the urine [25].This is consistent with

findings in previous studies done by Saez Llorens et al. in Panama and Riordan et al. in United Kingdom[26,27].

In the present study, the mean eGFR of the HIV-infected subjects with microalbuminuria was significantly lower than their uninfected counterparts. Mild renal impairment in this study (defined as eGFR of between 60-90ml/min/m²)[23] was noted in 21.4% of the HIV-infected subjects with microalbuminuria. This finding further buttresses the fact that microalbuminuria is an early marker of glomerular dysfunction. This underscores the need for routine screening of all children infected with HIV for latent renal damage. Similar findings have been reported by Okechukwu et al. in Abuja and Fredrick et al. in Tanzania[9,13]. This is lower than that reported by Ahouiet al. in Benin Republic (38.5%) but higher than report by Esezoboret al. in Lagos (13.3%)[28,29]. The varying rates is as a result of the different eGFR cut off values for renal impairment, the methods used in estimating GFR and the stage of HIV associated kidney disease of the subjects. The eGFR cut off values for the index study was higher (60 – 90) than the cut off values from the Lagos study(30 – 60),[29] but similar to that of the Benin Republic study[28]. Also, while the index study used the creatinine-based formula for GFR estimation, the Lagos study[29] used Cystatin C. The use of Cystatin C-based formula has been argued to be more accurate than the GFR derived from the widely used creatinine-based formula because it is less affected by non-glomerular factors such as lean mass, diet, and tubular secretion [11].

Renal ultrasound examination of 30 subjects with microalbuminuria in the index study revealed normal renal length and echogenicity in all (100%) of them. Ultrasound findings of HIV related kidney disease include normal or enlarged kidneys with increased echogenicity [30].The findings of normal renal length and echogenicity in this study buttresses the fact that microalbuminuria is an early manifestation of HIV related kidney disease. Ahouiet al. in Benin Republic reported

increased echogenicity in 25.6% of their subjects[28]. Other studies with finding of increased echogenicity include; Anochieet al. in Port Harcourt (100%), Okechukwu et al. in Abuja (4.7%), Fredrick et al. in Tanzania (39.2%)[9,13,30]. Increased echogenicity is a late manifestation of HIV related kidney disease which the subjects in the index study did not have. Anochieet al. in Port Harcourt and Ahouiet al. in Benin Republic studied subjects with fully established HIV related kidney disease which may account for the high prevalence of increased echogenicity in their studies compared to the index study[28,30].

The limitations of this current study include the fact that the study was cross sectional, thereby limiting longitudinal follow up of children with positive microalbuminuria. Additionally, the testing for microalbuminuria was conducted on random spot samples, as opposed to first morning urine samples, which may have included cases of transient albuminuria. Estimated GFR was only done for subjects with positive microalbuminuria due to cost implications. This limitation restricted the comparison of renal function between subjects who tested positive and those who tested negative for microalbuminuria, respectively. Furthermore, renal ultrasound scans were exclusively conducted for subjects with positive microalbuminuria due to cost constraints. This restriction also hindered the comparison of renal function between subjects with and without microalbuminuria, respectively.

5. Conclusion

Microalbuminuria was more prevalent in HIV-infected children than their uninfected counterparts and clinical stage four disease was the single most significant factor associated with MA. Measurement of microalbuminuria (instead of the dipstick urinalysis) should be included in the routine investigations for better management of HIV-infected children. This could help

identify those susceptible to development of renal disease early and prophylactic measures initiated. HIV-infected children with clinical stage 4 disease, advanced immunosuppression, unsuppressed viral load and those on tenofovir containing regimen may benefit from having their microalbuminuria assessed for early management and control.

References

1. United Nations Programme on HIV/AIDS - UNAIDS. Fact Sheet - Global AIDS Update 2019, 2018 Global HIV Statistics. Un aids. (2019). Accessed: August 15 2021: <http://www.unaids.org/en/resources/fact-sheet>.
2. Federal Ministry of Health. National Guidelines for HIV Prevention, Treatment and Care (2016). National Aids and Sti'S Control Programme. 2016.
3. Jindal AK, Tiewsoh K, Pilia RK. A review of renal disease in children with HIV infection. *Infect Dis*; 2018, 50:1-12. DOI:10.1080/23744235.2017.1371852
4. Leroy B, Pressac M, Bensman A, Sinnassamy P and Courpotin C. Renal status in human immunodeficiency virus infected children. A prospective study. In Proceedings of the International AIDS Conference. Amsterdam. 1992. <https://scholar.google.com/scholar?q=Leroy+B+Pressac+M+Bensman+A+Renal+status+in+human+immunodeficiency+virus+infected+children:+a+prospective+study+Proceedings+of+the+International+AIDS+Conference+1992+>
5. Priya Pais and Ellis D. Avner. Introduction to the Child with Proteinuria. Nelson Textbook of Paediatrics. 20th ed. R.M. Kliegman (ed): Elsevier, Philadelphia; 2016. 2:2518-21.

6. Mudi A, Alhaj BU, Hassan-Hanga F, Yahaya IA. Persistent microalbuminuria in human immunodeficiency virus infected children in Kano, Nigeria. *Int J Nephrol*. 2014, 2014:1-7. DOI:10.1155/2014/567838
7. Ekulu PM, Aloni MN, Harambat J, Makulo JRR, Lepira FB, Sumaili EK, et al. Microalbuminuria among HIV-infected antiretroviral therapy-naive children in the Democratic Republic of Congo. *Pediatr Nephrol*. 2016, 31:769-72. DOI:10.1007/s00467-015-3277-1
8. Ihekaike M, E Ocheke I OS. Microalbuminuria in children: A comparative study of HIV-Infected and non-Infected children in Jos, Nigeria. *J Pediatr Nephrol*. 2021,9. DOI:10.22037/jpn.v8i2.33547
9. Okechukwu A, Lawson J, Itanyi D, Dalilo M. Renal function abnormalities in HIV-infected children and adolescents on antiretroviral therapy at the University of Abuja Teaching Hospital, Gwagwalada, Nigeria: A cross-sectional study. *Int J Trop Dis Heal*. 2017, 26:1-12. DOI:10.9734/IJTDH/2017/36637
10. Bertilla Uzoma E, Henrietta Uchenna O, Anthony Nnaemeka I, Tagbo O. Screening for microalbuminuria in HIV-positive children in Enugu. *Int J Nephrol*. 2012, 2012:DOI:10.1155/2012/805834
11. Iduoriyekemwen NJ, Sadoh WE, Sadoh AE. Prevalence of renal disease in Nigerian children infected with the human immunodeficiency virus and on highly active antiretroviral therapy. *Saudi J Kidney Dis Transpl*. 2013, 24:172-177. DOI:10.4103/1319-2442.106364

12. Eke FU, Anochie IC, Okpere AN, Eneh AU, Ugwu RN, Ejilemele AA, Ugboma HU. Microalbuminuria in children with human immunodeficiency virus (HIV) infection in Port. Harcourt, Nigeria. *Niger J Med.* 2010, 19:298-301. DOI:10.4314/njm.v19i3.60214
13. Fredrick F, Francis JM, Ruggajo PJ, Maro EE. Renal abnormalities among HIV infected children at Muhimbili National Hospital (MNH) - Dar es Salaam, Tanzania. *BMC Nephrol.* 2016, 17:1-6. DOI:10.1186/s12882-016-0242-6
14. Mistry BJ. Relevance of microalbuminuria in screening for HIV-associated nephropathy. Electronic theses and Dissertations (ETD), WireSpace. 2010. <http://hdl.handle.net/10539/7650>
15. Mosten IK, Hamel BC, Kinabo GD. Prevalence of persistent microalbuminuria and associated factors among HIV infected children attending a tertiary hospital in Northern Tanzania: a cross sectional, analytical study. *Pan Afr Med J.* 2015, 20:251. DOI:10.11604/pamj.2015.20.251.5429
16. Sharma G, Mathai SS. Prevalence of asymptomatic microalbuminuria in HIV positive children in India. *Indian J Pediatr.* 2017, 84:417-419. DOI:10.1007/s12098-017-2294-4
17. Yenagoa FMC. (2017). Accessed: August 15, 2022: <https://fmcyenagoa.org.ng/>.
18. Udemé EE. Introduction to Research and Biostatistics. *Paediatrics and Child Health in a Tropical Region.* 3rd editio. Azubuike N (ed). African Educational Services, Owerri; 2016. 61-62.
19. Akahara C, Nwolisa E, Odinaka K, Okolo S. Assessment of antiretroviral treatment adherence among children attending care at a tertiary hospital in southeastern Nigeria. *J Trop Med.* 2017, 2017:DOI:10.1155/2017/3605850

20. Centers for Disease Control and Prevention. About Child & Teen BMI | Healthy Weight | CDC. About Child & Teen BMI | Healthy Weight | CDC. (2021). Accessed: August 22,2021:https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html#:~:text=For%20children%20and%20...
21. Madeira I: Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *ResidPediátr.* 2018, 8:59. DOI:10.25060/residpediatr-2018.v8n1-12
22. Diagnostics R. Micral-Test® strip.Product Information [Internet. (2021). Accessed: September 17 2021: <https://diagnostics.roche.com/global/en/products/instruments/micral-tests.html>.
23. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.. *Ann Intern Med.* 2003, 139:137-147. DOI:10.7326/0003-4819-139-2-200307150-00013
24. Symeonidou C, Standish R, Sahdev S, Katz RD, Morlese J, Malhotra A: Imaging and histopathologic features of HIV-related renal disease. *Radiographics.* 2008, 28:1339-1354. DOI:10.1148/rg.285075126
25. Jao J, Wyatt CM: Antiretroviral medications: adverse effects on the kidney. *Adv Chronic Kidney Dis.* 2010, 17:72-82. DOI:10.1053/j.ackd.2009.07.009
26. Saez-Llorens X, Castaño E, Rathore M, Church J, Deville J, Gaur A, et al. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression. *Pediatr Infect Dis J.* 2015, 34:376-82. DOI:10.1097/INF.0000000000000289

27. Riordan A, Judd A, Boyd K, Cliff D, Doerholt K, Lyall H, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. *Pediatr Infect Dis J*. 2009, 28:204-9. DOI:10.1097/INF.0b013e31818c8d2c.
28. Ahoui S, Agbeille F, Kpanidja G, Noudamadjo A, Agboton TBL, Eteka E, et al. Kidney Injury in children infected with HIV, followed at the teaching hospital of Borgou (Benin): epidemiological and clinical Aspects. *J Ren Hepatic Disord*. 2021, 5:50-56. <https://jrenhep.com/index.php/jrenhep/article/view/120>.
29. Esezobor CI, Iroha E, Oladipo O, Onifade E, Soriyan OO, Akinsulie AO, et al. Kidney function of HIV-infected children in Lagos, Nigeria: Using Filler's serum cystatin C-based formula. *J Int AIDS Soc*. 2010, 13:17-17. DOI:10.1186/1758-2652-13-17
30. Anochie IC, Eke FU, Okpere AN: Human immunodeficiency virus-associated nephropathy (HIVAN) in Nigerian children. *Pediatr Nephrol*. 2008, 23:117-22. DOI:10.1007/s00467-007-0621-0